薬物スクリーニング市場規模、シェア、動向、2030年までの世界予測

世界の薬物スクリーニング市場は、2025年の103億6,000万米ドルから2030年には212億9,000万米ドルに達し、年平均成長率（CAGR）15.5%で成長すると予測されています。薬物スクリーニング市場は、運輸、建設、製造業など、安全性が重視される分野における政府による義務化とリスクベースの検査の拡大によって牽引されています。
この成長は、世界的な薬物使用の増加に支えられています。2023年には世界で約3億1,600万人が薬物を使用しており、その増加率は人口増加率を上回ると予想されています。そのため、職場や公道における機能障害のリスクが高まっています。薬物関連の機能障害は、年間約130万人の死因となっている交通事故（RTI）の重要な要因であり、その93%は低所得国および中所得国で発生しています。このため、世界中で路上および事故後の薬物検査プログラムの必要性が高まっています。米国では、事故後の職場における薬物陽性率は2023年に10.4%に達し、マリファナの陽性率は25年ぶりの高水準となる7.5%に達しました。これは、成熟市場における同様のリスクパターンを示しており、無作為検査および事故後検査の導入を加速させています。その結果、雇用主や規制当局は、迅速で法的に正当化可能なスクリーニングおよび確認ソリューションを優先するようになり、病院は重要な臨床判断をサポートするために、ハイスループットLC-MSによる確定的毒性試験への依存度が高まっています。同時に、口腔液、唾液、毛髪検査の普及により、改ざんリスクを低減しながら最近の薬物使用をより正確に検出できるようになり、検査プロトコルが刷新されています。組織は、障害率の上昇と認定基準の厳格化に対応するため、従来の薬物スクリーニング技術のアップグレードを迫られています。

調査対象範囲

本調査レポートは、薬物スクリーニング市場を、提供内容（製品およびサービス）、サンプルの種類（尿サンプル、呼気サンプル、口腔液サンプル、毛髪サンプル、その他のサンプル）、薬物の種類（大麻、アルコール、コカイン、オピオイド、アンフェタミンおよびメタンフェタミン、その他の薬物）、エンドユーザー（薬物検査機関、職場、刑事司法制度および法執行機関、病院、薬物治療センター、個人ユーザー、疼痛管理センター、学校および大学、その他のエンドユーザー）、および地域（北米、欧州、アジア太平洋、ラテンアメリカ、中東およびアフリカ）別に分類しています。本レポートは、薬物スクリーニング市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーの詳細な分析により、事業概要、ソリューション、サービス、主要戦略、契約、パートナーシップ、合意、新製品および新サービスの発売、合併・買収、そして薬物スクリーニング市場に関連する最近の動向に関する洞察を提供しています。このレポートでは、薬物検査市場のエコシステムにおける今後の新興企業の競合分析について説明します。

このレポートを購入する理由

本レポートは、薬物スクリーニング市場とそのサブセグメントの収益数値に関する近似値に関する情報を提供し、市場リーダー/新規参入企業にとって役立ちます。本レポートは、ステークホルダーが競争環境を理解し、事業のポジショニングを改善し、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。また、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、課題、そして機会に関する情報を提供するのにも役立ちます。

本レポートでは、以下の点について洞察を提供しています。

• 薬物検査市場の成長に影響を与える主要な推進要因（違法薬物およびアルコールの消費量の増加、薬物およびアルコール検査を義務付ける厳格な法律の施行、薬物検査製品およびサービスに対する規制当局の承認件数の増加）、制約要因（イスラム諸国における飲酒禁止、職場における薬物検査の禁止）、機会（口腔液検査の普及、職場における指紋に基づく薬物検査の導入、新興経済国における高い成長機会）、課題（呼気アルコール濃度検知器の精度と特異性に関する懸念、薬物検査における偽陽性および偽陰性の結果）の分析
• 製品開発／イノベーション：薬物スクリーニング市場における今後の技術、研究開発活動、新製品・新サービスの発売に関する詳細な洞察
• 市場開発：収益性の高い市場に関する包括的な情報。本レポートでは、様々な地域における薬物スクリーニング市場を分析しています。
• 市場多様化：薬物スクリーニング市場における新製品・サービス、未開拓地域、最近の動向、投資に関する包括的な情報
• 競合評価：薬物スクリーニング市場におけるLabCorp（米国）、Quest Diagnostics Incorporated（米国）、Abbott（米国）、OraSure Technologies Inc.（米国）、Alfa Scientific Designs Inc.（米国）、Thermo Fisher Scientific Inc.（米国）、Drägerwerk AG & Co. KGaA（ドイツ）などの主要企業の市場シェア、成長戦略、サービス提供に関する詳細な評価

Report Description

The global drug screening market is projected to reach USD 21.29 billion by 2030 from USD 10.36 billion in 2025, at a CAGR of 15.5%. The drug screening market is being driven by expanding government mandates and risk-based testing across safety-sensitive sectors such as transportation, construction, and manufacturing. This growth is underpinned by rising global substance use. Around 316 million people worldwide used drugs in 2023, a rate increasing faster than population growth, heightening impairment risks in workplaces and on public roads. Drug-related impairment is a critical contributor to road traffic injuries (RTIs), which cause approximately 1.3 million deaths annually, with 93% occurring in low- and middle-income countries, reinforcing the need for roadside and post-incident drug testing programs globally. In the US, post-accident workplace drug positivity reached 10.4% in 2023, with marijuana positivity rising to a 25-year high of 7.5%, illustrating similar risk patterns in mature markets and accelerating adoption of random and post-incident testing. As a result, employers and regulators are prioritizing fast, legally defensible screening and confirmatory solutions, while hospitals increasingly rely on high-throughput LC-MS definitive toxicology testing to support critical clinical decisions. At the same time, broader acceptance of oral fluid, saliva, and hair testing is reshaping testing protocols by enabling more accurate detection of recent drug use with lower tampering risk, compelling organizations to upgrade conventional drug screening technologies in response to rising impairment rates and stricter accreditation standards.

“By offering, services segment to account for largest market share”

Based on offering, the services segment, which includes laboratory testing services and onsite testing services, is anticipated to fuel the drug screening market over the forecast period, as organizations continue to adopt comprehensive and managed testing services. Laboratory testing services assist in dealing with a large number of tests, confirmatory tests, and regulatory requirements, whereas onsite testing services facilitate rapid testing at the point of need. The rising trend of compliance-driven, random, and multi-panel testing programs, as well as the increasing use of alternative specimen types such as oral fluid and hair, is driving the demand for specialized service providers. This is also evident in the operational trends, which highlight that, according to the 2023 Quest Diagnostics Drug Testing Index, incidents of workforce test cheating jumped sharply, indicating the growing complexity and need for expert management and confirmatory services. In addition, workplace trends in 2025 highlight that scalability, regulatory compliance, and integrated reporting are key drivers for organizations outsourcing drug testing, rather than managing testing programs in-house. As testing volumes and expenses increase, organizations are increasingly adopting scalable, compliant, and service-oriented drug screening solutions, which support robust growth in the services market. In December 2022, Omega Laboratories launched the Urine Drugs of Abuse Testing Services in its state-of-the-art laboratory in Ontario, Canada. The laboratory offered urine drug testing from January 3, 2023, to complement its molecular testing.

“By end user, drug testing laboratories accounted for largest share of drug screening market in 2024.”

The global drug screening market is fueled by the growing prevalence of illicit drug use, occupational health and safety concerns, and changing medical and legal needs. Globally, it is estimated that 9% of the adult population between 15 and 64 years of age uses illicit drugs every year, with cannabis, opioids, and stimulants being the most prevalent, while drug-related deaths contribute to approximately 0.6 million deaths annually, emphasizing a substantial public health problem. In Europe, cannabis use is a problem for 8.4 % of adults, and drug-related deaths continue to increase, largely due to opioids and polysubstance use. These factors are fueling increasing post-incident, random, and routine drug screening in the workplace in safety-sensitive industries worldwide. The increasing use of non-invasive specimen types, such as oral fluid and hair, as well as the expansion of roadside and law enforcement drug testing, is improving the detection of recent drug use and preventing sample tampering.

“APAC to witness the highest growth rate during the forecast period”

The increasing prevalence of substance use and the structural need for outsourced laboratory testing are driving the market in Asia Pacific. In Australia, the 2022-2023 National Drug Strategy Household Survey estimates that 1.8 million people smoke daily, 2.5 million people have used cannabis in the past 12 months, 1.0 million people have used cocaine, and 6.6 million people engage in risky alcohol consumption, reflecting the continued demand for clinical toxicology and substance monitoring services in healthcare and occupational settings. Moreover, illicit substance use, including cocaine and e-cigarettes, is rising among young adults and women, expanding the tested population beyond the traditional high-risk group. In India, the numbers are even more substantial. National survey data show that 14.6% of the population (approximately 160 million people) are current alcohol users, 31 million people use cannabis, and over 20 million people use opioids, with nearly 6 million people in need of treatment services. Furthermore, 11.8 million people misuse sedatives, and an estimated 850,000 people inject drugs, representing a continued need for laboratory-based toxicology testing in hospitals, rehabilitation facilities, and public health settings.

The breakdown of primary participants is as given below:

• By Company Type – Tier 1: 60%, Tier 2: 30%, and Tier 3: 10%
• By Designation – C-level: 30%, Director-level: 50%, and Others: 20%
• By Region – North America: 45%, Europe: 20%, Asia Pacific: 25%, Rest of the world: 10%.

Labcorp (US), Quest Diagnostics Incorporated (US), and Abbott (US) are some of the key players in the drug screening market.

The study includes an in-depth competitive analysis of these key players in the drug screening market, with their company profiles, recent developments, and key market strategies.

Research Coverage

This research report categorizes the drug screening market by offering (products & services), sample type (urine samples, breath samples, oral fluid samples, hair samples, other samples), drug type (cannabis, alcohol, cocaine, opioids, amphetamine and methamphetamine, other drugs) end user (drug testing laboratories, workplaces, criminal justice systems and law enforcement agencies, hospitals, drug treatment centers, individual users, pain management centers, schools and colleges, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the drug screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions, and recent developments associated with the drug screening market. Competitive analysis of upcoming startups in the drug screening market ecosystem is covered in this report.

Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the drug screening market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing consumption of illicit drugs and alcohol, Enforcement of stringent laws mandating drug and alcohol testing, Increasing number of regulatory approvals for drug screening products and services) restraints (Ban on alcohol consumption in Islamic countries, Prohibition on workplace drug testing) opportunities (Popularity of oral fluid testing, Introduction of fingerprint-based drug testing at workplaces, High growth opportunities in emerging economies) challenges (Accuracy and specificity concerns in breathalyzers, False positive and negative results in drug screening) influencing the growth of the drug screening market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the drug screening market
• Market Development: Comprehensive information about lucrative markets; the report analyses the drug screening market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the drug screening market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like LabCorp (US), Quest Diagnostics Incorporated (US), Abbott (US), OraSure Technologies Inc. (US), Alfa Scientific Designs Inc. (US), Thermo Fisher Scientific Inc. (US), and Drägerwerk AG & Co. KGaA (Germany), among others, in the drug screening market

Table of Contents

1 INTRODUCTION 39
1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION 39
1.3 MARKET SCOPE 40
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 40
1.3.2 INCLUSIONS & EXCLUSIONS 41
1.3.3 YEARS CONSIDERED 42
1.4 CURRENCY CONSIDERED 42
1.5 LIMITATIONS 43
1.6 STAKEHOLDERS 43
1.7 SUMMARY OF CHANGES 44
2 EXECUTIVE SUMMARY 45
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 45
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 46
2.3 DISRUPTIVE TRENDS IN DRUG SCREENING MARKET 47
2.4 HIGH-GROWTH SEGMENTS 48
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 49
3 PREMIUM INSIGHTS 50
3.1 DRUG SCREENING MARKET OVERVIEW 50
3.2 DRUG SCREENING MARKET, BY OFFERING & REGION 51
3.3 DRUG SCREENING MARKET: GEOGRAPHIC SNAPSHOT 52
3.4 DRUG SCREENING MARKET: DEVELOPED VS. EMERGING ECONOMIES 52
4 MARKET OVERVIEW 53
4.1 INTRODUCTION 53
4.2 MARKET DYNAMICS 54
4.2.1 DRIVERS 54
4.2.1.1 Growing consumption of illicit drugs and alcohol 54
4.2.1.2 Enforcement of stringent laws mandating drug and alcohol testing 55
4.2.1.3 Increasing number of regulatory approvals for drug screening products & services 56
4.2.2 RESTRAINTS 57
4.2.2.1 Ban on alcohol consumption in Islamic countries 57
4.2.2.2 Prohibition on workplace drug testing 57
4.2.3 OPPORTUNITIES 58
4.2.3.1 Popularity of oral fluid testing 58
4.2.3.2 Introduction of fingerprint-based drug testing in workplaces 58
4.2.3.3 High growth opportunities in emerging economies 59
4.2.4 CHALLENGES 59
4.2.4.1 Accuracy and specificity concerns in breathalyzers 59
4.2.4.2 False positive and negative results in drug screening 60
4.3 UNMET NEEDS & WHITE SPACES 60
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 61
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 61
5 INDUSTRY TRENDS 63
5.1 PORTER’S FIVE FORCES ANALYSIS 63
5.1.1 BARGAINING POWER OF SUPPLIERS 64
5.1.2 BARGAINING POWER OF BUYERS 64
5.1.3 THREAT OF SUBSTITUTES 64
5.1.4 THREAT OF NEW ENTRANTS 65
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 65
5.2 MACROECONOMIC INDICATORS 65
5.2.1 INTRODUCTION 65
5.2.2 GDP TRENDS & FORECAST 65
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 66
5.3 VALUE CHAIN ANALYSIS 66
5.4 ECOSYSTEM ANALYSIS 68
5.5 PRICING ANALYSIS 70
5.5.1 INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES,
BY TYPE (2024) 70
5.5.2 INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES,
BY REGION (2024) 71
5.6 KEY CONFERENCES & EVENTS, 2026–2027 71
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 72
5.8 INVESTMENT & FUNDING SCENARIO 73
5.9 CASE STUDY ANALYSIS 74
5.10 IMPACT OF 2025 US TARIFFS ON DRUG SCREENING MARKET 76
5.10.1 INTRODUCTION 76
5.10.2 KEY TARIFF RATES 76
5.10.3 PRICE IMPACT ANALYSIS 77
5.10.4 IMPACT ON COUNTRY/REGION 77
5.10.4.1 US 77
5.10.4.2 Europe 78
5.10.4.3 Asia Pacific 79
5.10.5 IMPACT ON END-USE INDUSTRIES 79
5.10.5.1 Drug testing laboratories 79
5.10.5.2 Workplaces 79
5.10.5.3 Criminal justice systems & law enforcement agencies 80
5.10.5.4 Hospitals 80
5.10.5.5 Drug treatment centers 80
5.10.5.6 Individual users 80
5.10.5.7 Pain management centers 80
5.10.5.8 Schools & colleges 80
5.10.5.9 Other end users 81
6 STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS,
AND DIGITAL & AI ADOPTION 82
6.1 KEY EMERGING TECHNOLOGIES 82
6.1.1 LC-MS/MS & GC-MS-BASED CONFIRMATORY TESTING TECHNOLOGIES 82
6.1.2 AI-DRIVEN RESULT INTERPRETATION & QUALITY ASSURANCE TECHNOLOGIES 82
6.1.3 LABORATORY AUTOMATION & ROBOTICS TECHNOLOGIES 83
6.2 COMPLEMENTARY TECHNOLOGIES 83
6.2.1 MOBILE HEALTH (MHEALTH) & REMOTE COLLECTION TECHNOLOGIES 83
6.2.2 ANALYTICS & POPULATION-LEVEL DRUG USE SURVEILLANCE TOOLS 84
6.3 ADJACENT TECHNOLOGIES 84
6.3.1 FORENSIC CASE MANAGEMENT SYSTEMS 84
6.3.2 WORKFORCE BACKGROUND SCREENING/VERIFICATION SYSTEMS 85
6.4 TECHNOLOGY/PRODUCT ROADMAP 85
6.5 PATENT ANALYSIS 86
6.5.1 PATENT PUBLICATION TRENDS FOR DRUG SCREENING MARKET 86
6.5.2 INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS 87
6.6 FUTURE APPLICATIONS 90
6.6.1 AI-ENABLED INTELLIGENT SCREENING AND RESULT INTERPRETATION 90
6.6.2 CONTINUOUS AND PREDICTIVE DRUG MONITORING APPLICATIONS 91
6.6.3 DECENTRALIZED, AT-HOME, AND POINT-OF-CARE SCREENING EXPANSION 91
6.6.4 INTEGRATED COMPLIANCE, FORENSIC, AND PUBLIC HEALTH INTELLIGENCE PLATFORMS 91
6.6.5 PERSONALIZED AND THERAPEUTIC DRUG SCREENING APPLICATIONS 92
6.7 IMPACT OF AI/GEN AI ON DRUG SCREENING MARKET 92
6.7.1 INTRODUCTION 92
6.7.2 MARKET POTENTIAL OF AI/GEN AI IN DRUG SCREENING MARKET 93
6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 94
6.7.3.1 AI-driven transformation of preclinical toxicology screening at PathAI 94
6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS 95
6.7.4.1 Laboratory & toxicology operations 95
6.7.4.2 Laboratory information systems (LIS) & compliance infrastructure 95
6.7.4.3 Clinical care, workplace safety, and monitoring programs 96

6.7.5 USER READINESS AND IMPACT ASSESSMENT 96
6.7.5.1 User readiness 96
6.7.5.1.1 User A: Clinical, reference, and toxicology laboratories 96
6.7.5.1.2 User B: Healthcare providers, employers, and forensic agencies 96
6.7.5.2 Impact assessment 97
6.7.5.2.1 User A: Clinical, reference, and toxicology laboratories 97
6.7.5.2.1.1 Implementation 97
6.7.5.2.1.2 Impact 97
6.7.5.2.2 User B: Healthcare providers, employers, and forensic agencies 97
6.7.5.2.2.1 Implementation 97
6.7.5.2.2.2 Impact 97
7 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 98
7.1 INTRODUCTION 98
7.2 DECISION-MAKING PROCESS 98
7.3 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 99
7.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 99
7.3.2 BUYING CRITERIA 100
7.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 101
7.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 101
7.5.1 UNMET NEEDS 102
7.5.2 END-USER EXPECTATIONS 103
7.6 MARKET PROFITABILITY 103
8 REGULATORY LANDSCAPE 105
8.1 REGIONAL REGULATIONS & COMPLIANCE 105
8.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 106
8.1.2 REGULATORY FRAMEWORK 109
8.1.2.1 North America 109
8.1.2.2 Europe 110
8.1.2.3 Asia Pacific 111
8.1.2.4 Latin America 111
8.1.2.5 Middle East & Africa 112
8.1.3 INDUSTRY STANDARDS 112
9 DRUG SCREENING MARKET, BY OFFERING 113
9.1 INTRODUCTION 114
9.2 SERVICES 114
9.2.1 WORKFORCE DECENTRALIZATION, PANEL COMPLEXITY, AND LITIGATION-READY TESTING TO DRIVE SUSTAINED MARKET GROWTH 114
9.2.2 LABORATORY TESTING SERVICES 116
9.2.2.1 Ability to ensure analytical rigor and compliance with regulatory standards to drive demand 116
9.2.3 ON-SITE TESTING SERVICES 117
9.2.3.1 Ability to deliver rapid, point-of-care screening solutions to drive market growth 117
9.3 PRODUCTS 118
9.3.1 ANALYTICAL INSTRUMENTS MARKET, BY TYPE 120
9.3.1.1 Breathalyzers 122
9.3.1.1.1 Fuel-cell breathalyzers 123
9.3.1.1.1.1 Extremely high accuracy, sensitivity, and reliability to drive demand for fuel-cell breathalyzers 123
9.3.1.1.2 Semiconductor breathalyzers 124
9.3.1.1.2.1 Lower prices of semiconductor breathalyzers to drive adoption 124
9.3.1.1.3 Other breathalyzers 125
9.3.1.2 Immunoassay analyzers 126
9.3.1.2.1 Growing adoption of high‑throughput immunoassay platforms to power modern toxicology 126
9.3.1.3 Chromatography instruments 127
9.3.1.3.1 Advantages such as precise, high-sensitivity analysis in forensic, clinical, and regulatory laboratories to fuel growth 127
9.3.2 ANALYTICAL INSTRUMENTS MARKET, BY MODALITY 127
9.3.2.1 Handheld breathalyzers 128
9.3.2.1.1 Critical role in delivering fast, accurate, and portable alcohol screening to support market growth 128
9.3.2.2 Benchtop breathalyzers 129
9.3.2.2.1 Growing use of benchtop breathalyzers for drug detection analysis to drive growth 129
9.3.3 RAPID TESTING DEVICES 130
9.3.3.1 Urine testing devices 131
9.3.3.1.1 Drug testing cups 133
9.3.3.1.1.1 Reduced contact with urine sample to drive demand 133
9.3.3.1.2 Dip cards 133
9.3.3.1.2.1 Ability to provide qualitative results within minutes to propel market 133
9.3.3.1.3 Drug testing cassettes 134
9.3.3.1.3.1 Lower cost alternatives to drug testing cups and dip cards to boost adoption 134
9.3.3.2 Oral fluid testing devices 135
9.3.3.2.1 Rapid, non-invasive detection of recent drug use across workplace, clinical, and law enforcement settings to fuel growth 135
9.3.4 CONSUMABLES 136
9.3.4.1 Assay kits 137
9.3.4.1.1 Rapid, cost-effective, and high-throughput screening across drug testing applications to drive market 137
9.3.4.2 Sample collection devices 138
9.3.4.2.1 Reliable, tamper-resistant, and versatile drug testing across settings to support growth 138
9.3.4.3 Calibrators & controls 139
9.3.4.3.1 Ability to verify accuracy, precision, and reliability of screening and confirmatory test results to drive growth 139
9.3.4.4 Other consumables 140
10 DRUG SCREENING MARKET, BY SAMPLE TYPE 142
10.1 INTRODUCTION 143
10.2 URINE SAMPLES 143
10.2.1 RECENT ADVANCES TO STRENGTHEN ACCURACY AND RELIABILITY IN URINE DRUG TESTING 143
10.3 BREATH SAMPLES 145
10.3.1 BREATH ALCOHOL TESTS TO REGISTER WIDE USAGE IN WORKPLACE TESTING AND LAW ENFORCEMENT APPLICATIONS 145
10.4 ORAL FLUID SAMPLES 146
10.4.1 NON-INVASIVE SAMPLE COLLECTION AND LOW CHANCE OF ADULTERATION TO SUPPORT USAGE OF ORAL FLUID SAMPLES 146
10.5 HAIR SAMPLES 147
10.5.1 ABILITY OF HAIR SAMPLES TO PROVIDE INSIGHTS INTO LONG-TERM DRUG USE TO BOOST MARKET 147
10.6 OTHER SAMPLES 149
11 DRUG SCREENING MARKET, BY DRUG TYPE 150
11.1 INTRODUCTION 151
11.2 CANNABIS 151
11.2.1 GROWING CANNABIS USE AND REGULATORY COMPLEXITY TO DRIVE SUSTAINED DEMAND FOR DRUG SCREENING SOLUTIONS 151
11.3 ALCOHOL 153
11.3.1 REGULATORY ENFORCEMENT AND TECHNOLOGY INNOVATION TO STRENGTHEN ALCOHOL SCREENING ADOPTION 153
11.4 COCAINE 154
11.4.1 SHIFT TOWARD RAPID, DEFENSIBLE DETECTION TO POSITION COCAINE AS PRIORITY DRUG IN MODERN SCREENING PANELS 154
11.5 OPIOIDS 156
11.5.1 EXPANDED OPIOID PANELS AND ADVANCED CONFIRMATORY TECHNOLOGIES TO REINFORCE OPIOID SCREENING AS HIGH PRIORITY 156
11.6 AMPHETAMINES & METHAMPHETAMINES 157
11.6.1 ADVANCED ANALYTICS AND DIFFERENTIATION TESTING TO REDEFINE AMPHETAMINE & METHAMPHETAMINE DETECTION 157
11.7 OTHER DRUGS 159

12 DRUG SCREENING MARKET, BY END USER 161
12.1 INTRODUCTION 162
12.2 DRUG TESTING LABORATORIES 162
12.2.1 ADVANCED ANALYTICS, AUTOMATION, AND EXPANDING FORENSIC AND CLINICAL DEMAND TO DRIVE MARKET GROWTH 162
12.3 WORKPLACES 164
12.3.1 RISING NUMBER OF DRUG ABUSE CASES TO INCREASE WORKPLACE TESTING 164
12.4 CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES 165
12.4.1 HIGH SUBSTANCE-USE PREVALENCE AND DUI RISKS TO DRIVE MANDATORY DRUG & ALCOHOL TESTING 165
12.5 HOSPITALS 166
12.5.1 RISING EMERGENCY ADMISSIONS, OPIOID OVERDOSES, AND PATIENT SAFETY MANDATES TO DRIVE STRONG DEMAND 166
12.6 DRUG TREATMENT CENTERS 168
12.6.1 RISING ADOPTION OF MEDICATION-ASSISTED TREATMENT, RELAPSE MONITORING, AND FENTANYL DETECTION TO DRIVE DEMAND 168
12.7 INDIVIDUAL USERS 169
12.7.1 GROWING SELF-MONITORING, HOME TESTING, AND RECOVERY ACCOUNTABILITY TO EXPANDING INDIVIDUAL USE OF SCREENING 169
12.8 PAIN MANAGEMENT CENTERS 170
12.8.1 OPIOID PRESCRIBING OVERSIGHT AND PATIENT SAFETY MANDATES TO DRIVE INCREASED DRUG SCREENING 170
12.9 SCHOOLS & COLLEGES 171
12.9.1 MODERN TESTING AND AWARENESS PROGRAMS TO STRENGTHEN DRUG ABUSE PREVENTION IN SCHOOLS & COLLEGES 171
12.10 OTHER END USERS 173
13 DRUG SCREENING MARKET, BY REGION 175
13.1 INTRODUCTION 176
13.2 NORTH AMERICA 177
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 177
13.2.2 US 184
13.2.2.1 Regulatory enforcement and substance use prevalence drive drug screening market in US 184
13.2.3 CANADA 190
13.2.3.1 Public health surveillance, consumption trends, and enforcement & technological advancements to drive market 190
13.3 EUROPE 196
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 196
13.3.2 GERMANY 202
13.3.2.1 Strengthening drug screening adoption through public health policy and technological modernization to support market growth 202

13.3.3 FRANCE 208
13.3.3.1 Regulatory enforcement, transport safety, and forensic modernization to shape drug screening market 208
13.3.4 UK 213
13.3.4.1 Community-embedded testing, criminal justice demand, and real-time drug surveillance to shape UK drug screening market 213
13.3.5 ITALY 219
13.3.5.1 Strengthening drug screening market through roadside enforcement and analytical innovation & institutional capacity 219
13.3.6 SPAIN 225
13.3.6.1 Expanding drug screening adoption through road safety programs to drive market growth 225
13.3.7 REST OF EUROPE 230
13.4 ASIA PACIFIC 235
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 236
13.4.2 CHINA 243
13.4.2.1 Synthetic drug control and pharmaceutical innovation to drive drug screening market growth 243
13.4.3 JAPAN 248
13.4.3.1 Japan’s aging population and advanced digital infrastructure to drive rapid adoption 248
13.4.4 INDIA 253
13.4.4.1 Alcohol dominance, opioid misuse, and India’s role as global pharmaceutical hub to drive drug screening market growth 253
13.4.5 AUSTRALIA 259
13.4.5.1 Harm-reduction policy, workplace safety regulation, and roadside testing to drive drug screening market 259
13.4.6 SOUTH KOREA 264
13.4.6.1 Zero-tolerance drug policy, mandatory military service, and forensic-grade testing to shape drug screening market 264
13.4.7 REST OF ASIA PACIFIC 269
13.5 LATIN AMERICA 274
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 274
13.5.2 BRAZIL 280
13.5.2.1 Brazil’s drug screening market to expand amid road safety mandates, substance-use burden, and regulatory enforcement 280
13.5.3 MEXICO 286
13.5.3.1 Mexico’s drug screening market shaped by methamphetamine prevalence, cross-border labor dynamics, and public safety enforcement 286
13.5.4 REST OF LATIN AMERICA 291
13.6 MIDDLE EAST & AFRICA 296
13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 297
13.6.2 GCC COUNTRIES 303
13.6.2.1 Saudi Arabia 309
13.6.2.1.1 Public safety, diagnostic modernization, and evolving consumption patterns to boost market 309
13.6.2.2 UAE 314
13.6.2.2.1 Integrated safety enforcement, workplace testing, and diagnostic modernization to expand market in UAE 314
13.6.2.3 Rest of GCC Countries 319
13.6.3 SOUTH AFRICA 324
13.6.3.1 Rising substance use, workplace risk management, and advanced screening capabilities to fuel market growth 324
13.6.4 REST OF MIDDLE EAST & AFRICA 329
14 COMPETITIVE LANDSCAPE 335
14.1 OVERVIEW 335
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 335
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG SCREENING MARKET 335
14.3 REVENUE ANALYSIS, 2020–2024 337
14.4 MARKET SHARE ANALYSIS, 2024 338
14.5 BRAND COMPARISON 341
14.6 COMPANY VALUATION & FINANCIAL METRICS 342
14.6.1 FINANCIAL METRICS 342
14.6.2 COMPANY VALUATION 342
14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 343
14.7.1 STARS 343
14.7.2 EMERGING LEADERS 343
14.7.3 PERVASIVE PLAYERS 343
14.7.4 PARTICIPANTS 344
14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 345
14.7.5.1 Company footprint 345
14.7.5.2 Region footprint 346
14.7.5.3 Offering footprint 347
14.7.5.4 Sample type footprint 348
14.7.5.5 Drug type footprint 349
14.7.5.6 End-user footprint 350
14.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 351
14.8.1 PROGRESSIVE COMPANIES 351
14.8.2 RESPONSIVE COMPANIES 351
14.8.3 DYNAMIC COMPANIES 351
14.8.4 STARTING BLOCKS 351
14.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 353
14.8.5.1 Detailed list of key startups/SMEs 353
14.8.5.2 Competitive benchmarking of startups/SMEs 354

14.9 COMPETITIVE SCENARIO 355
14.9.1 PRODUCT LAUNCHES & ENHANCEMENTS 355
14.9.2 DEALS 356
14.9.3 OTHER DEVELOPMENTS 357
15 COMPANY PROFILES 358
15.1 KEY PLAYERS 358
15.1.1 LABCORP 358
15.1.1.1 Business overview 358
15.1.1.2 Products & services offered 359
15.1.1.3 Recent developments 360
15.1.1.3.1 Deals 360
15.1.1.4 MnM view 361
15.1.1.4.1 Key strengths 361
15.1.1.4.2 Strategic choices 361
15.1.1.4.3 Weaknesses & competitive threats 361
15.1.2 QUEST DIAGNOSTICS INCORPORATED 362
15.1.2.1 Business overview 362
15.1.2.2 Products & services offered 363
15.1.2.3 Recent developments 364
15.1.2.3.1 Product & service launches 364
15.1.2.3.2 Deals 364
15.1.2.4 MnM view 365
15.1.2.4.1 Key strengths 365
15.1.2.4.2 Strategic choices 366
15.1.2.4.3 Weaknesses & competitive threats 366
15.1.3 ABBOTT 367
15.1.3.1 Business overview 367
15.1.3.2 Products & services offered 369
15.1.3.3 MnM view 371
15.1.3.3.1 Key strengths 371
15.1.3.3.2 Strategic choices 371
15.1.3.3.3 Weaknesses & competitive threats 371
15.1.4 ORASURE TECHNOLOGIES INC. 372
15.1.4.1 Business overview 372
15.1.4.2 Products & services offered 374
15.1.4.3 Recent developments 374
15.1.4.3.1 Deals 374
15.1.4.4 MnM view 375
15.1.4.4.1 Key strengths 375
15.1.4.4.2 Strategic choices 375
15.1.4.4.3 Weaknesses & competitive threats 375
15.1.5 ALFA SCIENTIFIC DESIGNS INC. 376
15.1.5.1 Business overview 376
15.1.5.2 Products & services offered 377
15.1.5.3 MnM view 378
15.1.5.3.1 Key strengths 378
15.1.5.3.2 Strategic choices 378
15.1.5.3.3 Weaknesses & competitive threats 378
15.1.6 THERMO FISHER SCIENTIFIC INC. 379
15.1.6.1 Business overview 379
15.1.6.2 Products & services offered 381
15.1.6.3 Recent developments 384
15.1.6.3.1 Product developments 384
15.1.6.3.2 Deals 385
15.1.7 DRÄGERWERK AG & CO. KGAA 386
15.1.7.1 Business overview 386
15.1.7.2 Products & services offered 388
15.1.7.3 Recent developments 388
15.1.7.3.1 Product launches 388
15.1.8 LIFELOC TECHNOLOGIES, INC. 389
15.1.8.1 Business overview 389
15.1.8.2 Products & services offered 390
15.1.8.3 Recent developments 392
15.1.8.3.1 Other developments 392
15.1.9 MPD INC. 393
15.1.9.1 Business overview 393
15.1.9.2 Products & services offered 394
15.1.10 OMEGA LABORATORIES, INC. 395
15.1.10.1 Business overview 395
15.1.10.2 Products & services offered 396
15.1.10.3 Recent developments 396
15.1.10.3.1 Service launches 396
15.1.10.3.2 Deals 397
15.1.10.3.3 Other developments 397
15.1.11 PREMIER BIOTECH, INC. 398
15.1.11.1 Business overview 398
15.1.11.2 Products & services offered 399
15.1.11.3 Recent developments 400
15.1.11.3.1 Deals 400
15.1.12 PSYCHEMEDICS CORPORATION 401
15.1.12.1 Business overview 401
15.1.12.2 Products & services offered 402
15.1.12.3 Recent developments 403
15.1.12.3.1 Product launches & enhancements 403
15.1.12.3.2 Other developments 404
15.1.13 F. HOFFMANN-LA ROCHE LTD. 405
15.1.13.1 Business overview 405
15.1.13.2 Products & services offered 407
15.1.13.3 Recent developments 408
15.1.13.3.1 Deals 408
15.1.14 SHIMADZU CORPORATION 409
15.1.14.1 Business overview 409
15.1.14.2 Products & services offered 411
15.1.14.3 Recent developments 412
15.1.14.3.1 Product launches 412
15.1.14.3.2 Deals 413
15.1.15 SIEMENS HEALTHINEERS AG 414
15.1.15.1 Business overview 414
15.1.15.2 Products & services offered 416
15.1.15.3 Recent developments 417
15.1.15.3.1 Product launches 417
15.1.15.3.2 Deals 417
15.1.16 BIO-RAD LABORATORIES, INC. 419
15.1.16.1 Business overview 419
15.1.16.2 Products & services offered 421
15.1.16.3 Recent developments 422
15.1.16.3.1 Product enhancements 422
15.1.16.3.2 Deals 422
15.2 OTHER PLAYERS 424
15.2.1 CAREHEALTH AMERICA CORP. 424
15.2.2 ACCUSOURCEHR, INC. 425
15.2.3 CORDANT HEALTH SOLUTIONS 426
15.2.4 ADVACARE PHARMA 427
15.2.5 ACM GLOBAL LABORATORIES 428
15.2.6 MILLENNIUM HEALTH 429
15.2.7 CLINICAL REFERENCE LABORATORY, INC. 430
15.2.8 INTOXIMETERS 431
15.2.9 INTOXALOCK 432
16 RESEARCH METHODOLOGY 433
16.1 RESEARCH APPROACH 433
16.1.1 SECONDARY RESEARCH 433
16.1.1.1 Key data from secondary sources 434
16.1.2 PRIMARY RESEARCH 435
16.1.2.1 Primary sources 435
16.1.2.2 Key data from primary sources 436
16.1.2.3 Breakdown of primaries 437
16.1.2.4 Insights from primary experts 438
16.2 RESEARCH METHODOLOGY DESIGN 438
16.3 MARKET SIZE ESTIMATION 439
16.4 MARKET BREAKDOWN & DATA TRIANGULATION 444
16.5 MARKET SHARE ESTIMATION 444
16.6 STUDY ASSUMPTIONS 445
16.7 RESEARCH LIMITATIONS 445
16.7.1 METHODOLOGY-RELATED LIMITATIONS 445
16.8 RISK ASSESSMENT 446
17 APPENDIX 447
17.1 DISCUSSION GUIDE 447
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 452
17.3 CUSTOMIZATION OPTIONS 454
17.4 RELATED REPORTS 454
17.5 AUTHOR DETAILS 455

LIST OF TABLES

TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 42
TABLE 2 KEY PRODUCT & SERVICE LAUNCHES FOR DRUG & ALCOHOL TESTING,
2022–2025 56
TABLE 3 REGULATORY AUTHORITIES FOR DRUG & ALCOHOL
TESTING PRODUCTS & SERVICES 56
TABLE 4 DRUG SCREENING MARKET: PORTER’S FIVE FORCES ANALYSIS 64
TABLE 5 DRUG SCREENING MARKET: ROLE IN ECOSYSTEM 69
TABLE 6 INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES,
BY TYPE, 2024 (USD) 70
TABLE 7 INDICATIVE PRICING OF DRUG SCREENING PRODUCTS & SERVICES, BY REGION, 2024 (USD) 71
TABLE 8 DRUG SCREENING MARKET: KEY CONFERENCES & EVENTS, 2026–2027 72
TABLE 9 CASE 1: COMPREHENSIVE ORAL FLUID DUID TESTING PROGRAM 74
TABLE 10 CASE 2: HIGH-THROUGHPUT GC-MS DRUG SCREENING IN
FORENSIC URINE TESTING 75
TABLE 11 CASE 3: ORAL FLUID DRUG TESTING IMPLEMENTATION IN
A DRUG COURT PROGRAM 75
TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES 76
TABLE 13 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR
DRUG SCREENING MARKET 87
TABLE 14 DRUG SCREENING MARKET: LIST OF PATENTS/PATENT APPLICATIONS 89
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
TOP THREE END USERS (%) 99
TABLE 16 KEY BUYING CRITERIA FOR TOP THREE END USERS 101
TABLE 17 UNMET NEEDS IN DRUG SCREENING MARKET 102
TABLE 18 END-USER EXPECTATIONS IN DRUG SCREENING MARKET 103
TABLE 19 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 106
TABLE 20 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 107
TABLE 21 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 108
TABLE 22 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 108
TABLE 23 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 109
TABLE 24 REGULATORY SCENARIO OF NORTH AMERICA 109
TABLE 25 REGULATORY SCENARIO OF EUROPE 110
TABLE 26 REGULATORY SCENARIO OF ASIA PACIFIC 111
TABLE 27 REGULATORY SCENARIO OF LATIN AMERICA 111
TABLE 28 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 112
TABLE 29 DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 114
TABLE 30 DRUG SCREENING SERVICES MARKET: MAJOR PLAYERS & OFFERINGS 115
TABLE 31 DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 115
TABLE 32 DRUG SCREENING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 115
TABLE 33 DRUG SCREENING MARKET FOR LABORATORY TESTING SERVICES, BY REGION, 2023–2030 (USD MILLION) 117
TABLE 34 DRUG SCREENING MARKET FOR ON-SITE TESTING SERVICES, BY REGION,
2023–2030 (USD MILLION) 118
TABLE 35 DRUG SCREENING PRODUCTS MARKET: MAJOR PLAYERS & OFFERINGS 119
TABLE 36 DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 119
TABLE 37 DRUG SCREENING PRODUCTS MARKET, BY REGION, 2023–2030 (USD MILLION) 120
TABLE 38 DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY REGION,
2023–2030 (USD MILLION) 121
TABLE 39 DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 121
TABLE 40 DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 122
TABLE 41 DRUG SCREENING MARKET FOR BREATHALYZERS, BY REGION,
2023–2030 (USD MILLION) 123
TABLE 42 DRUG SCREENING MARKET FOR FUEL-CELL BREATHALYZERS, BY REGION,
2023–2030 (USD MILLION) 124
TABLE 43 DRUG SCREENING MARKET FOR SEMICONDUCTOR BREATHALYZERS, BY REGION, 2023–2030 (USD MILLION) 125
TABLE 44 DRUG SCREENING MARKET FOR OTHER BREATHALYZERS, BY REGION,
2023–2030 (USD MILLION) 125
TABLE 45 DRUG SCREENING MARKET FOR IMMUNOASSAY ANALYZERS, BY REGION,
2023–2030 (USD MILLION) 126
TABLE 46 DRUG SCREENING MARKET FOR CHROMATOGRAPHY INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION) 127
TABLE 47 DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION) 128
TABLE 48 DRUG SCREENING MARKET FOR HANDHELD BREATHALYZERS, BY REGION,
2023–2030 (USD MILLION) 129
TABLE 49 DRUG SCREENING MARKET FOR BENCHTOP BREATHALYZERS, BY REGION,
2023–2030 (USD MILLION) 130
TABLE 50 DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 131
TABLE 51 DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY REGION,
2023–2030 (USD MILLION) 131
TABLE 52 BLOOD SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 132
TABLE 53 DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY REGION,
2023–2030 (USD MILLION) 132
TABLE 54 DRUG SCREENING MARKET FOR DRUG TESTING CUPS, BY REGION,
2023–2030 (USD MILLION) 133
TABLE 55 DRUG SCREENING MARKET FOR DIP CARDS, BY REGION,
2023–2030 (USD MILLION) 134
TABLE 56 DRUG SCREENING MARKET FOR DRUG TESTING CASSETTES, BY REGION,
2023–2030 (USD MILLION) 135
TABLE 57 DRUG SCREENING MARKET FOR ORAL FLUID TESTING DEVICES, BY REGION, 2023–2030 (USD MILLION) 136
TABLE 58 DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 136
TABLE 59 DRUG SCREENING MARKET FOR CONSUMABLES, BY REGION,
2023–2030 (USD MILLION) 137
TABLE 60 DRUG SCREENING MARKET FOR ASSAY KITS, BY REGION,
2023–2030 (USD MILLION) 138
TABLE 61 DRUG SCREENING MARKET FOR SAMPLE COLLECTION DEVICES, BY REGION, 2023–2030 (USD MILLION) 139
TABLE 62 DRUG SCREENING MARKET FOR CALIBRATORS & CONTROLS, BY REGION,
2023–2030 (USD MILLION) 140
TABLE 63 DRUG SCREENING MARKET FOR OTHER CONSUMABLES, BY REGION,
2023–2030 (USD MILLION) 141
TABLE 64 DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 143
TABLE 65 DRUG SCREENING MARKET FOR URINE SAMPLES: MAJOR PLAYERS & OFFERINGS 144
TABLE 66 DRUG SCREENING MARKET FOR URINE SAMPLES, BY REGION,
2023–2030 (USD MILLION) 144
TABLE 67 DRUG SCREENING MARKET FOR BREATH SAMPLES:
MAJOR PLAYERS & OFFERINGS 145
TABLE 68 DRUG SCREENING MARKET FOR BREATH SAMPLES, BY REGION,
2023–2030 (USD MILLION) 146
TABLE 69 DRUG SCREENING MARKET FOR ORAL FLUID SAMPLES:
MAJOR PLAYERS & OFFERINGS 147
TABLE 70 DRUG SCREENING MARKET FOR ORAL FLUID SAMPLES, BY REGION,
2023–2030 (USD MILLION) 147
TABLE 71 DRUG SCREENING MARKET FOR HAIR SAMPLES: MAJOR PLAYERS & OFFERINGS 148
TABLE 72 DRUG SCREENING MARKET FOR HAIR SAMPLES, BY REGION,
2023–2030 (USD MILLION) 148
TABLE 73 DRUG SCREENING MARKET FOR OTHER SAMPLES: MAJOR PLAYERS & OFFERINGS 149
TABLE 74 DRUG SCREENING MARKET FOR OTHER SAMPLES, BY REGION,
2023–2030 (USD MILLION) 149
TABLE 75 DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 151
TABLE 76 DRUG SCREENING MARKET FOR CANNABIS: MAJOR PLAYERS & OFFERINGS 152
TABLE 77 DRUG SCREENING MARKET FOR CANNABIS, BY REGION,
2023–2030 (USD MILLION) 152
TABLE 78 DRUG SCREENING MARKET FOR ALCOHOL: MAJOR PLAYERS & OFFERINGS 153
TABLE 79 DRUG SCREENING MARKET FOR ALCOHOL, BY REGION,
2023–2030 (USD MILLION) 154
TABLE 80 DRUG SCREENING MARKET FOR COCAINE: MAJOR PLAYERS & OFFERINGS 155
TABLE 81 DRUG SCREENING MARKET FOR COCAINE, BY REGION,
2023–2030 (USD MILLION) 155
TABLE 82 DRUG SCREENING MARKET FOR OPIOIDS: MAJOR PLAYERS & OFFERINGS 156
TABLE 83 DRUG SCREENING MARKET FOR OPIDS, BY REGION, 2023–2030 (USD MILLION) 157
TABLE 84 DRUG SCREENING MARKET FOR AMPHETAMINES & METHAMPHETAMINES:
MAJOR PLAYERS & OFFERINGS 158
TABLE 85 DRUG SCREENING MARKET FOR AMPHETAMINES & METHAMPHETAMINES,
BY REGION, 2023–2030 (USD MILLION) 158
TABLE 86 DRUG SCREENING MARKET FOR OTHER DRUGS: MAJOR PLAYERS & OFFERINGS 159
TABLE 87 DRUG SCREENING MARKET FOR OTHER DRUGS, BY REGION,
2023–2030 (USD MILLION) 160
TABLE 88 DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION) 162
TABLE 89 DRUG SCREENING MARKET FOR DRUG TESTING LABORATORIES:
MAJOR PLAYERS & OFFERINGS 163
TABLE 90 DRUG SCREENING MARKET FOR DRUG TESTING LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 163
TABLE 91 DRUG SCREENING MARKET FOR WORKPLACES: MAJOR PLAYERS & OFFERINGS 164
TABLE 92 DRUG SCREENING MARKET FOR WORKPLACES, BY REGION,
2023–2030 (USD MILLION) 165
TABLE 93 US: DRUG SCREENING MARKET FOR WORKPLACES, BY TYPE,
2019–2026 (USD MILLION) 165
TABLE 94 DRUG SCREENING MARKET FOR CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES: MAJOR PLAYERS & OFFERINGS 166
TABLE 95 DRUG SCREENING MARKET FOR CRIMINAL JUSTICE SYSTEMS & LAW ENFORCEMENT AGENCIES, BY REGION, 2023–2030 (USD MILLION) 166
TABLE 96 DRUG SCREENING MARKET FOR HOSPITALS: MAJOR PLAYERS & OFFERINGS 167
TABLE 97 DRUG SCREENING MARKET FOR HOSPITALS, BY REGION,
2023–2030 (USD MILLION) 167
TABLE 98 DRUG SCREENING MARKET FOR DRUG TREATMENT CENTERS: MAJOR PLAYERS & OFFERINGS 168
TABLE 99 DRUG SCREENING MARKET FOR DRUG TREATMENT CENTERS, BY REGION,
2023–2030 (USD MILLION) 169
TABLE 100 DRUG SCREENING MARKET FOR INDIVIDUAL USERS: MAJOR PLAYERS & OFFERINGS 170
TABLE 101 DRUG SCREENING MARKET FOR INDIVIDUAL USERS, BY REGION,
2023–2030 (USD MILLION) 170
TABLE 102 DRUG SCREENING MARKET FOR PAIN MANAGEMENT CENTERS: MAJOR PLAYERS & OFFERINGS 171
TABLE 103 DRUG SCREENING MARKET FOR PAIN MANAGEMENT CENTERS, BY REGION, 2023–2030 (USD MILLION) 171
TABLE 104 DRUG SCREENING MARKET FOR SCHOOLS & COLLEGES: MAJOR PLAYERS & OFFERINGS 172
TABLE 105 DRUG SCREENING MARKET FOR SCHOOLS & COLLEGES, BY REGION,
2023–2030 (USD MILLION) 173
TABLE 106 DRUG SCREENING MARKET FOR OTHER END USERS: MAJOR PLAYERS & OFFERINGS 173
TABLE 107 DRUG SCREENING MARKET FOR OTHER END USERS, BY REGION,
2023–2030 (USD MILLION) 174
TABLE 108 DRUG SCREENING MARKET, BY REGION, 2023–2030 (USD MILLION) 176
TABLE 109 NORTH AMERICA: MACROECONOMIC INDICATORS 178
TABLE 110 NORTH AMERICA: DRUG SCREENING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 179
TABLE 111 NORTH AMERICA: DRUG SCREENING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 180
TABLE 112 NORTH AMERICA: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 180
TABLE 113 NORTH AMERICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 180
TABLE 114 NORTH AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 181
TABLE 115 NORTH AMERICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION) 181
TABLE 116 NORTH AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 181
TABLE 117 NORTH AMERICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 182
TABLE 118 NORTH AMERICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 182
TABLE 119 NORTH AMERICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION) 182
TABLE 120 NORTH AMERICA: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 183
TABLE 121 NORTH AMERICA: DRUG SCREENING MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 183
TABLE 122 NORTH AMERICA: DRUG SCREENING MARKET, BY END USER,
2023–2030 (USD MILLION) 184
TABLE 123 US: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 186
TABLE 124 US: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 186
TABLE 125 US: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 186
TABLE 126 US: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 187
TABLE 127 US: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 187
TABLE 128 US: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION) 187
TABLE 129 US: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 188
TABLE 130 US: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 188
TABLE 131 US: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 188
TABLE 132 US: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 189
TABLE 133 US: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 189
TABLE 134 US: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION) 190
TABLE 135 CANADA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 191
TABLE 136 CANADA: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 192
TABLE 137 CANADA: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 192
TABLE 138 CANADA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 192
TABLE 139 CANADA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 193
TABLE 140 CANADA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 193
TABLE 141 CANADA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 193
TABLE 142 CANADA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 194
TABLE 143 CANADA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 194
TABLE 144 CANADA: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 194
TABLE 145 CANADA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 195
TABLE 146 CANADA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION) 195
TABLE 147 EUROPE: MACROECONOMIC INDICATORS 197
TABLE 148 EUROPE: DRUG SCREENING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 149 EUROPE: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 198
TABLE 150 EUROPE: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 198
TABLE 151 EUROPE: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 198
TABLE 152 EUROPE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 199
TABLE 153 EUROPE: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 199
TABLE 154 EUROPE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 199
TABLE 155 EUROPE: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 200
TABLE 156 EUROPE: DRUG SCREENING MARKET FOR URINE TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 200
TABLE 157 EUROPE: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 200
TABLE 158 EUROPE: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 201
TABLE 159 EUROPE: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 201
TABLE 160 EUROPE: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION) 202
TABLE 161 GERMANY: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 203
TABLE 162 GERMANY: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 203
TABLE 163 GERMANY: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 204
TABLE 164 GERMANY: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION) 204
TABLE 165 GERMANY: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 204
TABLE 166 GERMANY: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 205
TABLE 167 GERMANY: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 205
TABLE 168 GERMANY: DRUG SCREENING MARKET FOR URINE TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 205
TABLE 169 GERMANY: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 206
TABLE 170 GERMANY: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 206
TABLE 171 GERMANY: DRUG SCREENING MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 207
TABLE 172 GERMANY: DRUG SCREENING MARKET, BY END USER,
2023–2030 (USD MILLION) 207
TABLE 173 FRANCE: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 209
TABLE 174 FRANCE: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 209
TABLE 175 FRANCE: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 209
TABLE 176 FRANCE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION) 210
TABLE 177 FRANCE: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 210
TABLE 178 FRANCE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 210
TABLE 179 FRANCE: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 180 FRANCE: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 211
TABLE 181 FRANCE: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 211
TABLE 182 FRANCE: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 212
TABLE 183 FRANCE: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 212
TABLE 184 FRANCE: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION) 213
TABLE 185 UK: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 215
TABLE 186 UK: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 215
TABLE 187 UK: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 215
TABLE 188 UK: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE,
2023–2030 (USD MILLION) 216
TABLE 189 UK: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 216
TABLE 190 UK: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION) 216
TABLE 191 UK: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 217
TABLE 192 UK: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 217
TABLE 193 UK: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 217
TABLE 194 UK: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 218
TABLE 195 UK: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 218
TABLE 196 UK: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION) 219
TABLE 197 ITALY: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 220
TABLE 198 ITALY: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 221
TABLE 199 ITALY: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 221
TABLE 200 ITALY: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION) 221
TABLE 201 ITALY: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 222
TABLE 202 ITALY: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION) 222
TABLE 203 ITALY: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 222
TABLE 204 ITALY: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 223
TABLE 205 ITALY: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 223
TABLE 206 ITALY: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 223
TABLE 207 ITALY: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 224
TABLE 208 ITALY: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION) 224
TABLE 209 SPAIN: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 226
TABLE 210 SPAIN: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 226
TABLE 211 SPAIN: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 226
TABLE 212 SPAIN: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION) 227
TABLE 213 SPAIN: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 227
TABLE 214 SPAIN: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 227
TABLE 215 SPAIN: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 228
TABLE 216 SPAIN: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 228
TABLE 217 SPAIN: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 228
TABLE 218 SPAIN: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 229
TABLE 219 SPAIN: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 229
TABLE 220 SPAIN: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION) 230
TABLE 221 REST OF EUROPE: DRUG SCREENING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 231
TABLE 222 REST OF EUROPE: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 231
TABLE 223 REST OF EUROPE: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 231
TABLE 224 REST OF EUROPE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 232
TABLE 225 REST OF EUROPE: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION) 232
TABLE 226 REST OF EUROPE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 232
TABLE 227 REST OF EUROPE: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 233
TABLE 228 REST OF EUROPE: DRUG SCREENING MARKET FOR URINE TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 233
TABLE 229 REST OF EUROPE: DRUG SCREENING MARKET FOR CONSUMABLES,
BY TYPE, 2023–2030 (USD MILLION) 233
TABLE 230 REST OF EUROPE: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 234
TABLE 231 REST OF EUROPE: DRUG SCREENING MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 234
TABLE 232 REST OF EUROPE: DRUG SCREENING MARKET, BY END USER,
2023–2030 (USD MILLION) 235
TABLE 233 ASIA PACIFIC: MACROECONOMIC INDICATORS 237
TABLE 234 ASIA PACIFIC: DRUG SCREENING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 238
TABLE 235 ASIA PACIFIC: DRUG SCREENING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 238
TABLE 236 ASIA PACIFIC: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 238
TABLE 237 ASIA PACIFIC: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 239
TABLE 238 ASIA PACIFIC: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 239
TABLE 239 ASIA PACIFIC: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 239
TABLE 240 ASIA PACIFIC: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 240
TABLE 241 ASIA PACIFIC: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 240
TABLE 242 ASIA PACIFIC: DRUG SCREENING MARKET FOR URINE TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 240
TABLE 243 ASIA PACIFIC: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 241
TABLE 244 ASIA PACIFIC: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 241
TABLE 245 ASIA PACIFIC: DRUG SCREENING MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 242
TABLE 246 ASIA PACIFIC: DRUG SCREENING MARKET, BY END USER,
2023–2030 (USD MILLION) 242
TABLE 247 CHINA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 243
TABLE 248 CHINA: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 244
TABLE 249 CHINA: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 244
TABLE 250 CHINA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 244
TABLE 251 CHINA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 245
TABLE 252 CHINA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 245
TABLE 253 CHINA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 245
TABLE 254 CHINA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 246
TABLE 255 CHINA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 246
TABLE 256 CHINA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 246
TABLE 257 CHINA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 247
TABLE 258 CHINA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION) 247
TABLE 259 JAPAN: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 249
TABLE 260 JAPAN: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 249
TABLE 261 JAPAN: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 249
TABLE 262 JAPAN: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION) 250
TABLE 263 JAPAN: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 250
TABLE 264 JAPAN: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 250
TABLE 265 JAPAN: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 251
TABLE 266 JAPAN: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 251
TABLE 267 JAPAN: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 251
TABLE 268 JAPAN: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 252
TABLE 269 JAPAN: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 252
TABLE 270 JAPAN: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION) 253
TABLE 271 INDIA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 254
TABLE 272 INDIA: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 255
TABLE 273 INDIA: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 255
TABLE 274 INDIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 255
TABLE 275 INDIA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 256
TABLE 276 INDIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION) 256
TABLE 277 INDIA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 256
TABLE 278 INDIA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 257
TABLE 279 INDIA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 257
TABLE 280 INDIA: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 257
TABLE 281 INDIA: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 258
TABLE 282 INDIA: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION) 258
TABLE 283 AUSTRALIA: DRUG SCREENING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 259
TABLE 284 AUSTRALIA: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 260
TABLE 285 AUSTRALIA: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 260
TABLE 286 AUSTRALIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 260
TABLE 287 AUSTRALIA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 261
TABLE 288 AUSTRALIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 261
TABLE 289 AUSTRALIA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 261
TABLE 290 AUSTRALIA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 262
TABLE 291 AUSTRALIA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 262
TABLE 292 AUSTRALIA: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 262
TABLE 293 AUSTRALIA: DRUG SCREENING MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 263
TABLE 294 AUSTRALIA: DRUG SCREENING MARKET, BY END USER,
2023–2030 (USD MILLION) 263
TABLE 295 SOUTH KOREA: DRUG SCREENING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 264
TABLE 296 SOUTH KOREA: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 265
TABLE 297 SOUTH KOREA: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 265
TABLE 298 SOUTH KOREA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 265
TABLE 299 SOUTH KOREA: DRUG SCREENING MARKET FOR BREATHALYZERS,
BY TYPE, 2023–2030 (USD MILLION) 266
TABLE 300 SOUTH KOREA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 266
TABLE 301 SOUTH KOREA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 266
TABLE 302 SOUTH KOREA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 267
TABLE 303 SOUTH KOREA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 267
TABLE 304 SOUTH KOREA: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 267
TABLE 305 SOUTH KOREA: DRUG SCREENING MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 268
TABLE 306 SOUTH KOREA: DRUG SCREENING MARKET, BY END USER,
2023–2030 (USD MILLION) 268
TABLE 307 REST OF ASIA PACIFIC: DRUG SCREENING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 269
TABLE 308 REST OF ASIA PACIFIC: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 269
TABLE 309 REST OF ASIA PACIFIC: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 270
TABLE 310 REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION) 270
TABLE 311 REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR BREATHALYZERS,
BY TYPE, 2023–2030 (USD MILLION) 270
TABLE 312 REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION) 271
TABLE 313 REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 271
TABLE 314 REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 271
TABLE 315 REST OF ASIA PACIFIC: DRUG SCREENING MARKET FOR CONSUMABLES,
BY TYPE, 2023–2030 (USD MILLION) 272
TABLE 316 REST OF ASIA PACIFIC: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 272
TABLE 317 REST OF ASIA PACIFIC: DRUG SCREENING MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 273
TABLE 318 REST OF ASIA PACIFIC: DRUG SCREENING MARKET, BY END USER,
2023–2030 (USD MILLION) 273
TABLE 319 LATIN AMERICA: MACROECONOMIC INDICATORS 275
TABLE 320 LATIN AMERICA: DRUG SCREENING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 275
TABLE 321 LATIN AMERICA: DRUG SCREENING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 276
TABLE 322 LATIN AMERICA: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 276
TABLE 323 LATIN AMERICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 276
TABLE 324 LATIN AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 277
TABLE 325 LATIN AMERICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION) 277
TABLE 326 LATIN AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 277
TABLE 327 LATIN AMERICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 278
TABLE 328 LATIN AMERICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 278
TABLE 329 LATIN AMERICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 278
TABLE 330 LATIN AMERICA: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 279
TABLE 331 LATIN AMERICA: DRUG SCREENING MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 279
TABLE 332 LATIN AMERICA: DRUG SCREENING MARKET, BY END USER,
2023–2030 (USD MILLION) 280
TABLE 333 BRAZIL: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 281
TABLE 334 BRAZIL: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 281
TABLE 335 BRAZIL: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 282
TABLE 336 BRAZIL: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 282
TABLE 337 BRAZIL: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 282
TABLE 338 BRAZIL: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 283
TABLE 339 BRAZIL: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 283
TABLE 340 BRAZIL: DRUG SCREENING MARKET FOR URINE TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 283
TABLE 341 BRAZIL: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 284
TABLE 342 BRAZIL: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 284
TABLE 343 BRAZIL: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 285
TABLE 344 BRAZIL: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION) 285
TABLE 345 MEXICO: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 287
TABLE 346 MEXICO: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 287
TABLE 347 MEXICO: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 287
TABLE 348 MEXICO: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 288
TABLE 349 MEXICO: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 288
TABLE 350 MEXICO: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 288
TABLE 351 MEXICO: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 289
TABLE 352 MEXICO: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 289
TABLE 353 MEXICO: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 289
TABLE 354 MEXICO: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 290
TABLE 355 MEXICO: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 290
TABLE 356 MEXICO: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION) 291
TABLE 357 REST OF LATIN AMERICA: DRUG SCREENING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 292
TABLE 358 REST OF LATIN AMERICA: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 292
TABLE 359 REST OF LATIN AMERICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 292
TABLE 360 REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION) 293
TABLE 361 REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR BREATHALYZERS,
BY TYPE, 2023–2030 (USD MILLION) 293
TABLE 362 REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION) 293
TABLE 363 REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 294
TABLE 364 REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 294
TABLE 365 REST OF LATIN AMERICA: DRUG SCREENING MARKET FOR CONSUMABLES,
BY TYPE, 2023–2030 (USD MILLION) 294
TABLE 366 REST OF LATIN AMERICA: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 295
TABLE 367 REST OF LATIN AMERICA: DRUG SCREENING MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 295
TABLE 368 REST OF LATIN AMERICA: DRUG SCREENING MARKET, BY END USER,
2023–2030 (USD MILLION) 296
TABLE 369 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 298
TABLE 370 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 298
TABLE 371 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 298
TABLE 372 MIDDLE EAST & AFRICA: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 299
TABLE 373 MIDDLE EAST & AFRICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 299
TABLE 374 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE,2023–2030 (USD MILLION) 299
TABLE 375 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR BREATHALYZERS,
BY TYPE, 2023–2030 (USD MILLION) 300
TABLE 376 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION) 300
TABLE 377 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 300
TABLE 378 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 301
TABLE 379 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR CONSUMABLES,
BY TYPE, 2023–2030 (USD MILLION) 301
TABLE 380 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 301
TABLE 381 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 302
TABLE 382 MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY END USER,
2023–2030 (USD MILLION) 302
TABLE 383 GCC COUNTRIES: DRUG SCREENING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 304
TABLE 384 GCC COUNTRIES: DRUG SCREENING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 304
TABLE 385 GCC COUNTRIES: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 304
TABLE 386 GCC COUNTRIES: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 305
TABLE 387 GCC COUNTRIES: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 305
TABLE 388 GCC COUNTRIES: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION) 305
TABLE 389 GCC COUNTRIES: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 306
TABLE 390 GCC COUNTRIES: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 306
TABLE 391 GCC COUNTRIES: DRUG SCREENING MARKET FOR URINE TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 306
TABLE 392 GCC COUNTRIES: DRUG SCREENING MARKET FOR CONSUMABLES,
BY TYPE, 2023–2030 (USD MILLION) 307
TABLE 393 GCC COUNTRIES: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 307
TABLE 394 GCC COUNTRIES: DRUG SCREENING MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 308
TABLE 395 GCC COUNTRIES: DRUG SCREENING MARKET, BY END USER,
2023–2030 (USD MILLION) 308
TABLE 396 SAUDI ARABIA: DRUG SCREENING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 309
TABLE 397 SAUDI ARABIA: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 310
TABLE 398 SAUDI ARABIA: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 310
TABLE 399 SAUDI ARABIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 310
TABLE 400 SAUDI ARABIA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 311
TABLE 401 SAUDI ARABIA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 311
TABLE 402 SAUDI ARABIA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 311
TABLE 403 SAUDI ARABIA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 312
TABLE 404 SAUDI ARABIA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 312
TABLE 405 SAUDI ARABIA: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 312
TABLE 406 SAUDI ARABIA: DRUG SCREENING MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 313
TABLE 407 SAUDI ARABIA: DRUG SCREENING MARKET, BY END USER,
2023–2030 (USD MILLION) 313
TABLE 408 UAE: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 315
TABLE 409 UAE: DRUG SCREENING SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 315
TABLE 410 UAE: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 315
TABLE 411 UAE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 316
TABLE 412 UAE: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE,
2023–2030 (USD MILLION) 316
TABLE 413 UAE: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION) 316
TABLE 414 UAE: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 317
TABLE 415 UAE: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE,
2023–2030 (USD MILLION) 317
TABLE 416 UAE: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 317
TABLE 417 UAE: DRUG SCREENING MARKET, BY SAMPLE TYPE, 2023–2030 (USD MILLION) 318
TABLE 418 UAE: DRUG SCREENING MARKET, BY DRUG TYPE, 2023–2030 (USD MILLION) 318
TABLE 419 UAE: DRUG SCREENING MARKET, BY END USER, 2023–2030 (USD MILLION) 319
TABLE 420 REST OF GCC COUNTRIES: DRUG SCREENING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 320
TABLE 421 REST OF GCC COUNTRIES: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 320
TABLE 422 REST OF GCC COUNTRIES: DRUG SCREENING PRODUCTS MARKET, BY TYPE, 2023–2030 (USD MILLION) 320
TABLE 423 REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION) 321
TABLE 424 REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR BREATHALYZERS,
BY TYPE, 2023–2030 (USD MILLION) 321
TABLE 425 REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION) 321
TABLE 426 REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 322
TABLE 427 REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 322
TABLE 428 REST OF GCC COUNTRIES: DRUG SCREENING MARKET FOR CONSUMABLES,
BY TYPE, 2023–2030 (USD MILLION) 322
TABLE 429 REST OF GCC COUNTRIES: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 323
TABLE 430 REST OF GCC COUNTRIES: DRUG SCREENING MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 323
TABLE 431 REST OF GCC COUNTRIES: DRUG SCREENING MARKET, BY END USER,
2023–2030 (USD MILLION) 324
TABLE 432 SOUTH AFRICA: DRUG SCREENING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 325
TABLE 433 SOUTH AFRICA: DRUG SCREENING SERVICES MARKET, BY TYPE,
2023–2030 (USD MILLION) 325
TABLE 434 SOUTH AFRICA: DRUG SCREENING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 325
TABLE 435 SOUTH AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY TYPE, 2023–2030 (USD MILLION) 326
TABLE 436 SOUTH AFRICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION) 326
TABLE 437 SOUTH AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS,
BY MODALITY, 2023–2030 (USD MILLION) 326
TABLE 438 SOUTH AFRICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 327
TABLE 439 SOUTH AFRICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES,
BY TYPE, 2023–2030 (USD MILLION) 327
TABLE 440 SOUTH AFRICA: DRUG SCREENING MARKET FOR CONSUMABLES, BY TYPE,
2023–2030 (USD MILLION) 327
TABLE 441 SOUTH AFRICA: DRUG SCREENING MARKET, BY SAMPLE TYPE,
2023–2030 (USD MILLION) 328
TABLE 442 SOUTH AFRICA: DRUG SCREENING MARKET, BY DRUG TYPE,
2023–2030 (USD MILLION) 328
TABLE 443 SOUTH AFRICA: DRUG SCREENING MARKET, BY END USER,
2023–2030 (USD MILLION) 329
TABLE 444 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 330
TABLE 445 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING SERVICES MARKET,
BY TYPE, 2023–2030 (USD MILLION) 330
TABLE 446 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 331
TABLE 447 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY TYPE, 2023–2030 (USD MILLION) 331
TABLE 448 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR BREATHALYZERS, BY TYPE, 2023–2030 (USD MILLION) 331
TABLE 449 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR ANALYTICAL INSTRUMENTS, BY MODALITY, 2023–2030 (USD MILLION) 332
TABLE 450 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR RAPID TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 332
TABLE 451 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET FOR URINE TESTING DEVICES, BY TYPE, 2023–2030 (USD MILLION) 332
TABLE 452 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET
FOR CONSUMABLES, BY TYPE, 2023–2030 (USD MILLION) 333
TABLE 453 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET,
BY SAMPLE TYPE, 2023–2030 (USD MILLION) 333
TABLE 454 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET,
BY DRUG TYPE, 2023–2030 (USD MILLION) 334
TABLE 455 REST OF MIDDLE EAST & AFRICA: DRUG SCREENING MARKET,
BY END USER, 2023–2030 (USD MILLION) 334
TABLE 456 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG SCREENING, JANUARY 2022–DECEMBER 2025 335
TABLE 457 DRUG SCREENING MARKET: DEGREE OF COMPETITION 339
TABLE 458 DRUG SCREENING MARKET: REGION FOOTPRINT 346
TABLE 459 DRUG SCREENING MARKET: OFFERING FOOTPRINT 347
TABLE 460 DRUG SCREENING MARKET: SAMPLE TYPE FOOTPRINT 348
TABLE 461 DRUG SCREENING MARKET: DRUG TYPE FOOTPRINT 349
TABLE 462 DRUG SCREENING MARKET: END-USER FOOTPRINT 350
TABLE 463 DRUG SCREENING MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 353
TABLE 464 DRUG SCREENING MARKET: COMPETITIVE BENCHMARKING
OF KEY EMERGING PLAYERS/STARTUPS, BY REGION 354
TABLE 465 DRUG SCREENING MARKET: COMPETITIVE BENCHMARKING
OF KEY EMERGING PLAYERS/STARTUPS, BY OFFERING 354
TABLE 466 DRUG SCREENING MARKET: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2022– DECEMBER 2025 355
TABLE 467 DRUG SCREENING MARKET: DEALS, JANUARY 2022–DECEMBER 2025 356
TABLE 468 DRUG SCREENING MARKET: OTHER DEVELOPMENTS,
JANUARY 2022–DECEMBER 2025 357
TABLE 469 LABCORP: COMPANY OVERVIEW 358
TABLE 470 LABCORP: PRODUCTS & SERVICES OFFERED 359
TABLE 471 LABCORP: DEALS, JANUARY 2022–DECEMBER 2025 360
TABLE 472 QUEST DIAGNOSTICS INCORPORATED: COMPANY OVERVIEW 362
TABLE 473 QUEST DIAGNOSTICS INCORPORATED: PRODUCTS & SERVICES OFFERED 363
TABLE 474 QUEST DIAGNOSTICS INCORPORATED: PRODUCT & SERVICE LAUNCHES,
JANUARY 2022–DECEMBER 2025 364
TABLE 475 QUEST DIAGNOSTICS INCORPORATED: DEALS, JANUARY 2022–DECEMBER 2025 364
TABLE 476 ABBOTT: COMPANY OVERVIEW 367
TABLE 477 ABBOTT: PRODUCTS & SERVICES OFFERED 369
TABLE 478 ORASURE TECHNOLOGIES INC.: COMPANY OVERVIEW 372
TABLE 479 ORASURE TECHNOLOGIES INC.: PRODUCTS & SERVICES OFFERED 374
TABLE 480 ORASURE TECHNOLOGIES INC.: DEALS, JANUARY 2022–DECEMBER 2025 374
TABLE 481 ALFA SCIENTIFIC DESIGNS INC.: COMPANY OVERVIEW 376
TABLE 482 ALFA SCIENTIFIC DESIGNS INC.: PRODUCTS & SERVICES OFFERED 377
TABLE 483 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 379
TABLE 484 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED 381
TABLE 485 THERMO FISHER SCIENTIFIC INC.: PRODUCT DEVELOPMENTS,
JANUARY 2022–DECEMBER 2025 384
TABLE 486 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–DECEMBER 2025 385
TABLE 487 DRÄGERWERK AG & CO. KGAA: COMPANY OVERVIEW 386
TABLE 488 DRÄGERWERK AG & CO. KGAA: PRODUCTS & SERVICES OFFERED 388
TABLE 489 DRÄGERWERK AG & CO. KGAA: PRODUCT LAUNCHES,
JANUARY 2022–DECEMBER 2025 388
TABLE 490 LIFELOC TECHNOLOGIES, INC.: COMPANY OVERVIEW 389
TABLE 491 LIFELOC TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED 390
TABLE 492 LIFELOC TECHNOLOGIES, INC.: OTHER DEVELOPMENTS,
JANUARY 2022–DECEMBER 2025 392
TABLE 493 MPD INC.: COMPANY OVERVIEW 393
TABLE 494 MPD INC.: PRODUCTS & SERVICES OFFERED 394
TABLE 495 OMEGA LABORATORIES, INC.: COMPANY OVERVIEW 395
TABLE 496 OMEGA LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED 396
TABLE 497 OMEGA LABORATORIES, INC.: SERVICE LAUNCHES,
JANUARY 2022–DECEMBER 2025 396
TABLE 498 OMEGA LABORATORIES, INC.: DEALS, JANUARY 2022–DECEMBER 2025 397
TABLE 499 OMEGA LABORATORIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 397
TABLE 500 PREMIER BIOTECH, INC.: COMPANY OVERVIEW 398
TABLE 501 PREMIER BIOTECH, INC.: PRODUCTS & SERVICES OFFERED 399
TABLE 502 PREMIER BIOTECH, INC.: DEALS, JANUARY 2022–DECEMBER 2025 400
TABLE 503 PSYCHEMEDICS CORPORATION: COMPANY OVERVIEW 401
TABLE 504 PSYCHEMEDICS CORPORATION: PRODUCTS & SERVICES OFFERED 402
TABLE 505 PSYCHEMEDICS CORPORATION: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2022–DECEMBER 2025 403
TABLE 506 PSYCHEMEDICS CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022–DECEMBER 2025 404
TABLE 507 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 405
TABLE 508 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS & SERVICES OFFERED 407
TABLE 509 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–DECEMBER 2025 408
TABLE 510 SHIMADZU CORPORATION: COMPANY OVERVIEW 409
TABLE 511 SHIMADZU CORPORATION: PRODUCTS & SERVICES OFFERED 411
TABLE 512 SHIMADZU CORPORATION: PRODUCT LAUNCHES,
JANUARY 2022–DECEMBER 2025 412
TABLE 513 SHIMADZU CORPORATION: DEALS, JANUARY 2022–DECEMBER 2025 413
TABLE 514 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 414
TABLE 515 SIEMENS HEALTHINEERS AG: PRODUCTS & SERVICES OFFERED 416
TABLE 516 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES,
JANUARY 2022–DECEMBER 2025 417
TABLE 517 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022–DECEMBER 2025 417
TABLE 518 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 419
TABLE 519 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED 421
TABLE 520 BIO-RAD LABORATORIES, INC.: PRODUCT ENHANCEMENTS,
JANUARY 2022–DECEMBER 2025 422
TABLE 521 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–DECEMBER 2025 422
TABLE 522 CAREHEALTH AMERICA CORP.: COMPANY OVERVIEW 424
TABLE 523 ACCUSOURCEHR, INC.: COMPANY OVERVIEW 425
TABLE 524 CORDANT HEALTH SOLUTIONS: COMPANY OVERVIEW 426
TABLE 525 ADVACARE PHARMA: COMPANY OVERVIEW 427
TABLE 526 ACM GLOBAL LABORATORIES: COMPANY OVERVIEW 428
TABLE 527 MILLENNIUM HEALTH: COMPANY OVERVIEW 429
TABLE 528 CLINICAL REFERENCE LABORATORY, INC.: COMPANY OVERVIEW 430
TABLE 529 INTOXIMETERS: COMPANY OVERVIEW 431
TABLE 530 INTOXALOCK: COMPANY OVERVIEW 432
TABLE 531 RISK ASSESSMENT: DRUG SCREENING MARKET 446

LIST OF FIGURES

FIGURE 1 DRUG SCREENING MARKET SEGMENTATION & REGIONAL SCOPE 40
FIGURE 2 MARKET SCENARIO 45
FIGURE 3 GLOBAL DRUG SCREENING MARKET, 2023–2030 46
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN
DRUG SCREENING MARKET, 2022–2025 46
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF DRUG SCREENING MARKET 47
FIGURE 6 HIGH-GROWTH SEGMENTS IN DRUG SCREENING MARKET, 2025–2030 48
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DRUG SCREENING MARKET,
IN TERMS OF VALUE, DURING FORECAST PERIOD 49
FIGURE 8 EXPANDING WORKPLACE SAFETY MANDATES AND RISING SUBSTANCE ABUSE AWARENESS TO DRIVE MARKET GROWTH 50
FIGURE 9 DRUG SCREENING PRODUCTS MARKET IN NORTH AMERICA ACCOUNTED FOR LARGEST SHARE IN 2024 51
FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 52
FIGURE 11 GROWTH RATES OF EMERGING ECONOMIES TO BE HIGHER THAN
THOSE OF DEVELOPED ECONOMIES DURING FORECAST PERIOD 52
FIGURE 12 DRUG SCREENING MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 54
FIGURE 13 DRUG SCREENING MARKET: PORTER’S FIVE FORCES ANALYSIS 63
FIGURE 14 DRUG SCREENING MARKET: VALUE CHAIN ANALYSIS (2024) 67
FIGURE 15 DRUG SCREENING MARKET: ECOSYSTEM ANALYSIS 69
FIGURE 16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 73
FIGURE 18 PATENT PUBLICATION TRENDS IN DRUG CREENING MARKET, 2015–2025 87
FIGURE 19 JURISDICTION & TOP APPLICANT ANALYSIS FOR DRUG SCREENING MARKET 87
FIGURE 20 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR DRUG SCREENING MARKET (JANUARY 2015 TO DECEMBER 2025) 88
FIGURE 21 MARKET POTENTIAL OF AI/GEN AI ON DRUG SCREENING ACROSS INDUSTRIES 93
FIGURE 22 IMPACT OF AI/GEN AI ON INTERCONNECTED & ADJACENT ECOSYSTEMS 95
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 99
FIGURE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS 100
FIGURE 25 NORTH AMERICA: DRUG SCREENING MARKET SNAPSHOT 179
FIGURE 26 ASIA PACIFIC: DRUG SCREENING MARKET SNAPSHOT 237
FIGURE 27 REVENUE ANALYSIS OF KEY PLAYERS IN DRUG SCREENING MARKET, 2020–2024 338
FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS IN DRUG SCREENING MARKET, 2024 339
FIGURE 29 DRUG SCREENING MARKET: BRAND COMPARATIVE ANALYSIS 341
FIGURE 30 EV/EBITDA OF KEY VENDORS 342
FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 342
FIGURE 32 DRUG SCREENING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 344
FIGURE 33 DRUG SCREENING MARKET: COMPANY FOOTPRINT 345
FIGURE 34 DRUG SCREENING MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2024 352
FIGURE 35 LABCORP: COMPANY SNAPSHOT (2024) 359
FIGURE 36 QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT (2024) 363
FIGURE 37 ABBOTT: COMPANY SNAPSHOT (2024) 368
FIGURE 38 ORASURE TECHNOLOGIES INC.: COMPANY SNAPSHOT (2024) 373
FIGURE 39 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 380
FIGURE 40 DRÄGERWERK AG & CO. KGAA: COMPANY SNAPSHOT (2024) 387
FIGURE 41 LIFELOC TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024) 390
FIGURE 42 PSYCHEMEDICS CORPORATION: COMPANY SNAPSHOT (2024) 402
FIGURE 43 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 406
FIGURE 44 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2024) 410
FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2025) 415
FIGURE 46 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024) 420
FIGURE 47 RESEARCH DESIGN 433
FIGURE 48 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 437
FIGURE 49 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 439
FIGURE 50 BOTTOM-UP APPROACH 440
FIGURE 51 TOP-DOWN APPROACH 441
FIGURE 52 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN DRUG SCREENING INDUSTRY 442
FIGURE 53 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 442
FIGURE 54 DATA TRIANGULATION METHODOLOGY 444

---

---